Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tagraxofusp + decitabine
- Development stage
- Phase 2
- Lead developer
- Stemline Therapeutics
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
Tagraxofusp + decitabine is an investigational combination therapy being evaluated for the treatment of myeloid malignancies, including chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). Tagraxofusp (Elzonris) is a first-in-class CD123-targeted therapy composed of recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin (DT388) payload. It functions by binding to the IL-3 receptor alpha chain (CD123) on the surface of malignant cells, internalizing, and subsequently inhibiting protein synthesis via ADP-ribosylation of elongation factor 2, leading to apoptosis. Decitabine is a hypomethylating agent that acts as a nucleoside metabolic inhibitor; it incorporates into DNA and inhibits DNA methyltransferases, resulting in DNA hypomethylation and the restoration of normal function to genes critical for cellular differentiation and proliferation. This combination is currently being investigated in a Phase I/II clinical trial (NCT05038592) sponsored by the M.D. Anderson Cancer Center to determine the safety and efficacy of the regimen in patients with high-risk myeloid disorders.
- Other names
- tagraxofusp-erzs + decitabineSL-401 + decitabine
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on tagraxofusp + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tagraxofusp + decitabine.